Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update
Vertex's stock heads for all-time high as non-opioid painkiller shows promise
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals
Editas Medicine Shares Climb 20% on 3Q Revenue Growth, Narrower Loss
Editas Medicine 3Q Loss/Shr 55c >EDIT
Editas Medicine Shares Jump After Stifel Turns Bullish
Geron Taps Michelle Robertson to Succeed Olivia Bloom as Finance Chief
Editas Medicine 2Q Loss/Shr 56c >EDIT
Gene Editing Is Working. Wall Street Is Taking Notice.
Editas Medicine Shares Fall 15% on Pricing of Secondary Stock Offering
Stocks to Watch: Ammo, Editas Medicine
Editas Medicine Shares Sink 5.7% after Secondary Stock Offering
Editas Medicine: Announces Appointment of Erick J. Lucera as Chief Fincl Officer >EDIT
Editas Medicine 1Q Loss/Shr 71c >EDIT
Editas Medicine Gets Orphan Drug Designation for EDIT-301
Crispr Therapeutics Stock Gains on Hope for Sickle-Cell Gene Therapy
Crispr Therapeutics Stock Gains on Hope for Sickle-Cell Gene Therapy
Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead
Patent Ruling Is a Setback for Gene-Editing Firms Tied to Crispr Nobelists
Gene-Editing Start-Ups Are Being Courted. Big Pharma Senses a Buying Opportunity.
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.